ADAG Quote, Financials, Valuation and Earnings

CASI Pharmaceuticals, Inc. has a net margin of -- compared to Adagene, Inc.'s net margin of -353.92%. Adagene, Inc.'s return on equity of -56.44% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.

Adagene, Inc. has a consensus price target of $9.22, signalling upside risk potential of 398.61%. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 431.07%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Adagene, Inc., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Adagene, Inc..

Adagene, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.

Adagene, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adagene, Inc. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Adagene, Inc. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Adagene, Inc.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Adagene, Inc.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adagene, Inc. is 832.60x versus 0.46x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

China Pharma Holdings, Inc. has a net margin of -- compared to Adagene, Inc.'s net margin of -86.16%. Adagene, Inc.'s return on equity of -56.44% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.

Adagene, Inc. has a consensus price target of $9.22, signalling upside risk potential of 398.61%. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Adagene, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe Adagene, Inc. is more attractive than China Pharma Holdings, Inc..

Adagene, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.

Adagene, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adagene, Inc. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.

Adagene, Inc. quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. Adagene, Inc.'s net income of -- is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, Adagene, Inc.'s price-to-earnings ratio is -- while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adagene, Inc. is 832.60x versus 1.06x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech Ltd. has a net margin of -- compared to Adagene, Inc.'s net margin of --. Adagene, Inc.'s return on equity of -56.44% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.

Adagene, Inc. has a consensus price target of $9.22, signalling upside risk potential of 398.61%. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Adagene, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe Adagene, Inc. is more attractive than Sinovac Biotech Ltd..

Adagene, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.

Adagene, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Adagene, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.

Adagene, Inc. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. Adagene, Inc.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, Adagene, Inc.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adagene, Inc. is 832.60x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab Ltd. has a net margin of -- compared to Adagene, Inc.'s net margin of -30.98%. Adagene, Inc.'s return on equity of -56.44% beat Zai Lab Ltd.'s return on equity of -26.7%.

Adagene, Inc. has a consensus price target of $9.22, signalling upside risk potential of 398.61%. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.17 which suggests that it could grow by 164.64%. Given that Adagene, Inc. has higher upside potential than Zai Lab Ltd., analysts believe Adagene, Inc. is more attractive than Zai Lab Ltd..

Adagene, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.

Adagene, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adagene, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.

Adagene, Inc. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Adagene, Inc.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, Adagene, Inc.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adagene, Inc. is 832.60x versus 4.51x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.